Date:5/6/2009

and 77,132 in 2008) (1) -- Accumulated other comprehensive loss (317) (286) Accumulated deficit (827) (668) ----- ----- Total Shareholders' Equity attributable to Solutia 336 521 Equity attributable to noncontrolling interest 6 8 --- --- Total Shareholders' Equity 342 529 --- --- Total Liabilities and Shareholders' Equity $3,438 $3,734 ====== ====== SOLUTIA INC. CONSOLIDATED STATEMENT OF CASH FLOWS (Dollars in millions) (Unaudited) Successor Predecessor --------- ----------- Three One Two Months Month Months Ended Ended Ended March 31, March 31, February 29, 2009 2008 2008 --------- ---- -------- INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS OPERATING ACTIVITIES: Net income (loss) attributable to Solutia $(159) ($30) $1,454 Adjustments to reconcile net income (loss) to net cash used in o
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related biology technology :

1. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results